COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13/08/2024 - 22:05

FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro forma June 30, 2024, cash, cash equivalents, investments and [...]

Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

13/08/2024 - 22:05

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13/08/2024 - 22:05

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical [...]

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13/08/2024 - 22:01

BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

13/08/2024 - 22:01

Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024 SEATTLE and VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage [...]

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

13/08/2024 - 22:01

— Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024 — Preclinical data presented at the American Thoracic Society [...]

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024

13/08/2024 - 22:01

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast [...]

Teknova Reports Second Quarter 2024 Financial Results

13/08/2024 - 22:01

Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-Tek SM Production and RUO+ manufacturing grade Company [...]

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

13/08/2024 - 22:01

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 [...]

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

13/08/2024 - 22:00

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81. [...]

MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent

13/08/2024 - 22:00

Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products [...]

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

12/08/2024 - 22:20

NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients [...]

Sanara MedTech Inc. Announces Second Quarter 2024 Results

12/08/2024 - 22:15

FORT WORTH, TX, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

12/08/2024 - 22:15

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors [...]

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

12/08/2024 - 22:14

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5 [...]

Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock

12/08/2024 - 22:12

DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of [...]

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

12/08/2024 - 22:10

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp [...]

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

12/08/2024 - 22:05

Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted [...]

Spectral AI Announces 2024 Second Quarter Financial Results

12/08/2024 - 22:05

Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 Million Cash Position of $6.9 Million On [...]